Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2014)
Adalimumab dose reduction in psoriasis: results in a series of 12 patients
C. Conrad, M. Gilliet (2018)
Psoriasis: from Pathogenesis to Targeted TherapiesClinical Reviews in Allergy & Immunology, 54
K. Gordon, A. Gottlieb, R. Langely, P. Kerkhof, K. Belasco, M. Sundaram, M. Okun, L. Serra (2015)
Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruptionJournal of the European Academy of Dermatology and Venereology, 29
T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson, V. Montori (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.JAMA, 295 19
U. Mrowietz, K. Kragballe, K. Reich, P. Spuls, C. Griffiths, A. Nast, J. Franke, C. Antoniou, P. Arenberger, F. Balieva, M. Bylaitė, O. Correia, E. Daudén, P. Gisondi, L. Iversen, L. Kemény, M. Lahfa, T. Nijsten, T. Rantanen, A. Reich, T. Rosenbach, S. Segaert, Catherine Smith, T. Talme, B. Volc-Platzer, N. Yawalkar (2010)
Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 303
Fotiadou (2012)
Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.J Eur Acad Dermatol Venereol, 26
G. Carretero, L. Puig, J. Carrascosa, L. Ferrándiz, R. Ruiz‐Villaverde, P. Cueva, I. Belinchón, E. Vilarrasa, R. Rio, J. Sánchez-Carazo, A. López-Ferrer, F. Peral, S. Armesto, N. Eirís, J. Mitxelena, J. Vilar-Alejo, M. Martin, C. Soria (2018)
Redefining the therapeutic objective in psoriatic patients candidates for biological therapyJournal of Dermatological Treatment, 29
Soonawala (2012)
‘Non-inferiority’ trials: tips for the critical reader: research methodology 3 [in Dutch].Ned Tijdschr Geneeskd, 156
J. Cook, J. Hislop, T. Adewuyi, K. Harrild, D. Altman, C. Ramsay, C. Fraser, B. Buckley, P. Fayers, I. Harvey, A. Briggs, J. Norrie, D. Fergusson, I. Ford, L. Vale (2014)
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.Health technology assessment, 18 28
J. Na, Jun Kim, Kyoung-Chan Park, S. Youn (2008)
Low‐dose etanercept therapy in moderate to severe psoriasis in KoreanThe Journal of Dermatology, 35
(2013)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.JAMA, 310 20
R. Cook, B. Dickens, M. Fathalla (2003)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.The Journal of the American College of Dentists, 81 3
Kim Papp, Alan Menter, Y. Poulin, Yihua Gu, Eric Sasso (2013)
Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension studyJournal of the European Academy of Dermatology and Venereology, 27
G. Borm, J. Fransen, Wim Lemmens (2007)
A simple sample size formula for analysis of covariance in randomized clinical trials.Journal of clinical epidemiology, 60 12
Gordon (2015)
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.J Eur Acad Dermatol Venereol, 29
T. Taniguchi, S. Noda, Naomi Takahashi, H. Yoshimura, Kyoko Mizuno, M. Adachi (2013)
An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatmentJournal of the European Academy of Dermatology and Venereology, 27
A. López-Ferrer, E. Vilarrasa, Ignasi Gich, Lluís Puig (2013)
Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centreBritish Journal of Dermatology, 169
J. Bezooijen, M. Doorn, M. Schreurs, B. Koch, H. Velthuis, E. Prens, T. Gelder (2017)
Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility StudyTherapeutic Drug Monitoring, 39
Research Original Investigation Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis
Christiane, Druml, Wolzt, Pleiner (2000)
World Medical Association Declaration of HelsinkiInternational Journal of Pharmaceutical Medicine, 14
J. Zweegers, J. Groenewoud, J. Reek, M. Otero, P. Kerkhof, R. Driessen, P. Lümig, M. Njoo, P. Ossenkoppele, J. Mommers, M. Koetsier, W. Arnold, M. Andriessen, A. Kuijpers, M. Berends, Wietske Kievit, E. Jong (2017)
Comparison of the 1‐ and 5‐year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registryBritish Journal of Dermatology, 176
Taniguchi (2013)
An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.J Eur Acad Dermatol Venereol, 27
O. Baniandrés, V. Rodríguez-Soria, R. Romero-Jiménez, R. Suárez (2015)
Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.Actas dermo-sifiliograficas, 106 7
H. Chiu, R. Hui, T. Tsai, Y. Chen, Nien-Feng Liao, Po-Hua Chen, Po-Ju Lai, Ting‐Shun Wang, Yu-Huei Huang (2019)
Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An eight-year multicenter study.Journal of the American Academy of Dermatology
A. Blauvelt, L. Ferris, Paul Yamauchi, Abrar Qureshi, Craig Leonardi, Kamyar Farahi, S. Fakharzadeh, M. Hsu, Shu Li, Marc Chevrier, Kevin Smith, K. Goyal, Yanqing Chen, Ernesto Muñoz-Elías, K. Duffin (2017)
Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)British Journal of Dermatology, 177
D. Soonawala, O. Dekkers (2012)
['Non-inferiority' trials. Tips for the critical reader. Research methodology 3].Nederlands tijdschrift voor geneeskunde, 156 19
Papp (2013)
Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.J Eur Acad Dermatol Venereol, 27
J. Zweegers, B. Roosenboom, P. Kerkhof, J. Reek, M. Otero, S. Atalay, A. Kuijpers, M. Koetsier, W. Arnold, M. Berends, L. Weppner‐Parren, M. Bijen, M. Njoo, J. Mommers, P. Lümig, R. Driessen, W. Kievit, E. Jong (2017)
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohortBritish Journal of Dermatology, 176
S. Atalay, J. Reek, L. Vugt, M. Otero, P. Kerkhof, A. Broeder, W. Kievit, E. Jong (2017)
Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trialBMC Dermatology, 17
Jacob Cohen (1969)
Statistical Power Analysis for the Behavioral SciencesThe SAGE Encyclopedia of Research Design
C. Fotiadou, E. Lazaridou, E. Sotiriou, D. Ioannides (2012)
Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centreJournal of the European Academy of Dermatology and Venereology, 26
Na (2008)
Low-dose etanercept therapy in moderate to severe psoriasis in Korean.J Dermatol, 35
López-Ferrer (2013)
Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.Br J Dermatol, 169
R. Romero-Jiménez, V. Escudero-Vilaplana, O. Rodriguez, E. Martín, Ana Mayo, M. Sáez (2018)
Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasisJournal of Dermatological Treatment, 29
This noninferiority randomized clinical trial investigates whether dose reduction of biologics for stable psoriasis is noninferior to usual care in patients with plaque psoriasis.
JAMA Dermatology – American Medical Association
Published: Apr 12, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.